WallStSmart

Charming Medical Limited Class A Ordinary Shares (MCTA)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1384533% more annual revenue ($66.57B vs $4.81M). MRK leads profitability with a 4.8% profit margin vs -0.5%. MRK trades at a lower P/E of 116.1x. MRK earns a higher WallStSmart Score of 36/100 (F).

MCTA

Avoid

11

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 4.0Quality: 5.0
Piotroski: 2/9

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MCTA.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MCTA0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

MCTA4 concerns · Avg: 2.8/10
Market CapQuality
$445.55M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
419.4x2/10

Premium valuation, high expectations priced in

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : MCTA

MCTA has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : MCTA

The primary concerns for MCTA are Market Cap, Operating Margin, Piotroski F-Score. A P/E of 419.4x leaves little room for execution misses.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

MCTA profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 11/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Charming Medical Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?